Lilly reports retatrutide cut weight and knee osteoarthritis pain in trial
Lilly executive Kenneth Custer said the triple agonist affected body weight, pain and physical function in patients with obesity and knee osteoarthritis.
MH
By Maren Holt · Senior Reporter, GLP-1
May 21 03:00 ETSource: livenowfox.com
The wire
- 01Eli Lilly said trial results for retatrutide, a first-in-class triple agonist, showed effects on body weight, pain and physical function in people with obesity and knee osteoarthritis.
- 02Patients with obesity and knee osteoarthritis often face restricted mobility and eventual joint replacement, making the population a distinct target from general weight management.
- 03The account comes from company statements and press reporting; full endpoint data, dosing detail and comparator results were not detailed in the report.
From the source
Read at livenowfox.comRetatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial
Eli Lilly logo (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)